ProMIS Neurosciences (PMN) Times Interest Earned (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Times Interest Earned came in at -$120.81 in Q1 2026, down 45747.61% on a QoQ basis from -$0.26 in Q4 2025.
ProMIS Neurosciences (PMN) Times Interest Earned (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Times Interest Earned data on file, last reported at -$120.81 in Q1 2026.
- Quarterly Times Interest Earned changed N/A year-over-year to -$120.81 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$578.32 (down 327.08% YoY) and the FY2025 annual result came in at -$0.98, down 85.75% from the prior year.
- Times Interest Earned fell to -$120.81 in Q1 2026, from -$0.26 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.26 in Q4 2025 to a low of -$1250.3 in Q3 2022.
- A 5-year average of -$174.52 and a median of -$41.12 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned tumbled 8407.87% — and 2023, when it surged 97.33%.
- Tracing PMN's Times Interest Earned over 5 years: stood at -$1250.3 in 2022, then soared by 95.96% to -$50.45 in 2023, then sank by 449.34% to -$277.17 in 2024, then surged by 99.9% to -$0.26 in 2025, then tumbled by 45747.61% to -$120.81 in 2026.
- The last three Times Interest Earned figures came in at -$120.81 (Q1 2026), -$0.26 (Q4 2025), and -$277.17 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.74 |
| Mar 31, 2026 | -120.81 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2024 | -277.17 |
| Jun 30, 2024 | -41.12 |
| Mar 31, 2024 | -24.39 |
| Dec 31, 2023 | -50.45 |
| Sep 30, 2023 | -33.38 |
| Jun 30, 2023 | -58.96 |
| Sep 30, 2022 | -1,250.34 |
| Jun 30, 2022 | -36.22 |
| Mar 31, 2022 | -26.65 |
| Dec 31, 2021 | -32.48 |
| Sep 30, 2021 | -14.70 |
| Jun 30, 2021 | -8.27 |